HHS moves to let compounding pharmacies make select peptides as China tightens biotech exports but permits foreign licensing

The HHS announced a policy that would allow compounding pharmacies to produce certain peptide drugs, expanding access and potentially lowering costs.

The move is part of the Trump administration's broader effort to adjust pharmaceutical regulations, aiming to give pharmacies more flexibility in preparing specialty therapies.

Meanwhile, China signaled it will tighten controls on biotech exports, but it will still allow licensing agreements with foreign drugmakers, suggesting a selective approach to international collaboration.

These policy shifts could affect supply chains and market dynamics for peptide therapeutics and biotech products, prompting companies to monitor regulatory developments in both the United States and China.